ART Advanced Research Technologies Inc.
The SoftScan® optical breast imaging device is commercialized by ART
Advanced Research Technologies in Canada and in Europe. SoftScan® uses
near-infrared laser light to obtain 3D images of the breast that
characterize cellular structure and tissue blood perfusion.
The technology addresses a critical need for a breast tissue analysis
device that provides functional and physiological information about a
lesion, including tissue perfusion, blood oxygen and water content, which
enables physicians to characterize it as benign or malignant.
- Emits no ionizing radiation, so any number of scans can be done
without risk.
- As a treatment-monitoring tool, can allow oncologists to see
immediately if a course of treatment is working and then adjust or
interrupt treatment. This could lead to shorter treatments, less
suffering, better results and lower costs for the health care system.
- Works even through dense breast tissue, typical of younger women.
- High specificity allows characterization of tumours as malignant or
benign.
Keywords: molecular imaging, treatment /patient monitoring, drug
development, diagnostic imaging, breast cancer, breast imaging, optical
imaging, time-domain imaging, non-invasive imaging, oncology
Contacts
ART Advanced Research Technologies Inc.
2300 Alfred-Nobel Boulevard
Montréal (Quebec) CANADA
H4S 2A4
Email:
softscan@art.ca
Website: www.art.ca
|